Advanced Cell Diagnostics, Inc. (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry.
ACD’s products and services are based on its proprietary RNAscope® Technology, the first multiplex fluorescent and chromogenic in situ hybridization platform capable of detecting and quantifying RNA biomarkers in situ at single molecule sensitivity.
In addition to its ongoing efforts to develop proprietary diagnostic tests for cancer management, ACD also establishes partnerships with pharmaceutical and biotechnology companies to validate biomarkers for targeted therapeutic development. These internal and external efforts will continue to position ACD as a leader in molecular diagnostics and companion diagnostics.
The company’s technology overcomes critical hurdles in the identification and validation of biomarkers for companion diagnostics. ACD’s RNAscope® platform provides a new way of localizing and measuring RNA in situ with exceptional levels of sensitivity, specificity, and the ability to multiplex. Turnaround time for a new assay is reduced to three weeks. These advantages make the technology a powerful tool to address the issue of patient and disease heterogeneity, thus shortening the path to personalized medicine.
- 定量检测：专业的Spot Studio Software
Step 2 目的RNA与特性的双“Z”探针进行杂交，目的探针是寡聚核苷酸探针，在探针的一端有与预放大系统结合的位点；
Step 3 预放大系统与目的探针杂交，放大系统与预放大系统杂交，最后标签探针与放大系统特异性杂交，在标签探针的一端是显色或者荧光基团；
Step 4 在明场或者荧光显微镜下观察显色样品。